人乳头瘤病毒感染且细胞学正常或低度异常女性的分诊:ARTISTIC试验队列10年随访证据
HPV16/18感染者的CIN3+风险远高于其他高危型HPV感染者。作者认为对细胞学正常或低度异常且HPV阳性者立即转诊阴道镜或一年后仍HPV阳性再转诊可能不必要,低度病变可安全复测以识别持续HPV感染者。
要点
- HPV16/18合并临界/低度细胞学者10年CIN3+累积风险19.4%(95%CI 15.8-23.8%)。
- HPV16/18合并正常细胞学者10年CIN3+累积风险10.7%(95%CI 8.3-13.9%)。
- 其他高危HPV型合并正常细胞学者10年CIN3+累积风险3.2%(95%CI 2.2-4.5%)。
核心结论
- CIN3风险局限于持续型别特异性HPV感染者,部分基因分型检测至少识别HPV16/18对有效风险分层至关重要。
- 对HPV阳性且临界或低度细胞学者立即转诊阴道镜、对细胞学正常且HPV阳性者一年后仍阳性再转诊可能不必要。
- 低度病变可安全复测以识别持续HPV感染者。
- 细胞学正常女性中HPV16/18者1年、其他高危HPV者2年的召回间隔有依据,临界/低度细胞学女性也可考虑。
- 须权衡极少进展超过IA期的浸润癌风险与减少阴道镜转诊对患者及NHS的益处。
主要发现
- HPV16/18合并临界/低度细胞学者10年CIN3+累积风险19.4%(95%CI 15.8-23.8%),合并正常细胞学者10.7%(95%CI 8.3-13.9%)。
- 其他HPV型合并临界/低度细胞学者10年CIN3+累积风险7.3%(95%CI 5.4-9.7%),合并正常细胞学者3.2%(95%CI 2.2-4.5%)。
- 379例细胞学正常至低度异常且新发HPV感染者10年CIN3+累积风险2.9%(95%CI 1.6-5.2%)。
关键数值与推荐
- HPV16/18合并临界/低度细胞学10年CIN3+累积风险19.4%(95%CI 15.8-23.8%)。
- HPV16/18合并正常细胞学10年CIN3+累积风险10.7%(95%CI 8.3-13.9%)。
- 其他HPV型合并临界/低度细胞学10年CIN3+累积风险7.3%(95%CI 5.4-9.7%)。
- 其他HPV型合并正常细胞学10年CIN3+累积风险3.2%(95%CI 2.2-4.5%)。
- 细胞学正常至低度异常且新发HPV感染者10年CIN3+累积风险2.9%(95%CI 1.6-5.2%)。
临床怎么用
- 部分基因分型检测至少识别HPV16/18对有效风险分层至关重要。
- 细胞学正常女性中HPV16/18者1年、其他高危HPV者2年的召回间隔有依据,临界/低度细胞学女性也可考虑。
- 对HPV阳性且临界或低度细胞学者立即转诊阴道镜、对细胞学正常且HPV阳性者一年后仍阳性再转诊可能不必要。
- 低度病变可安全复测以识别持续HPV感染者。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To estimate long-term cervical intraepithelial neoplasia grade 3 (CIN3) risks associated with different triage strategies for human papillomavirus positive (HPV+) women with a view to reducing unnecessary referrals. DESIGN: The ARTISTIC trial cohort was recruited in Manchester in 2001-03 and was followed up for CIN3 and cancer notification through national registration until December 2015. RESULTS: The 10-year cumulative risk of CIN3+ was much higher for women with HPV16/18 infection (19.4%, 95% CI 15.8-23.8% with borderline/low-grade cytology and 10.7%, 95% CI 8.3-13.9% with normal cytology) than for those with other HPV types (7.3%, 95% CI 5.4-9.7% with borderline/low-grade cytology and 3.2%, 95% CI 2.2-4.5% with normal cytology). Among the 379 women with normal to low-grade cytology and new HPV infection, the 10-year cumulative CIN3+ risk was 2.9% (95% CI 1.6-5.2%). CONCLUSIONS: The CIN3 risk is confined to women with persistent type-specific HPV so partial genotyping test assays identifying HPV16/18 as a minimum are essential for efficient risk stratification. Immediate referral to colposcopy for HPV+ women with borderline or low-grade cytology and referral after a year if still HPV+ with normal cytology may be unnecessary. Low-grade lesions can safely be retested to identify those with persistent HPV. Recall intervals of 1 year for HPV16/18 and 2 years for other high-risk HPVs are justified for women with normal cytology and might also be considered for women with borderline/low-grade cytology. The minimal risk of invasive cancer that has progressed beyond stage 1A must be weighed against the advantages for patients and the NHS of reducing the number of referrals to colposcopy. TWEETABLE ABSTRACT: Cervical screening would be better for women and cheaper for the NHS if women with HPV and normal to low-grade cytology were retested after a year or two when many infections will have cleared.
引用
- Gilham C, Sargent A, Peto J, et al. Triaging women with human papillomavirus infection and normal cytology or low-grade dyskaryosis: evidence from 10-year follow up of the ARTISTIC trial cohort. BJOG. 2019. PMID: 31541495. doi:10.1111/1471-0528.15957
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。